DexCom Inc (DXCM)vsNeuroone Medical Technologies Corp (NMTC)
DXCM
DexCom Inc
$75.14
+0.39%
HEALTHCARE · Cap: $29.58B
NMTC
Neuroone Medical Technologies Corp
$1.70
+3.03%
HEALTHCARE · Cap: $15.32M
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 37774% more annual revenue ($4.82B vs $12.72M). DXCM leads profitability with a 19.3% profit margin vs -52.2%. DXCM earns a higher WallStSmart Score of 72/100 (B).
DXCM
Strong Buy72
out of 100
Grade: B
NMTC
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.6%
Fair Value
$656.95
Current Price
$75.14
$581.81 discount
Intrinsic value data unavailable for NMTC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Earnings expanding 92.2% YoY
Strong operational efficiency at 21.4%
15.0% revenue growth
Revenue surging 72.5% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Trading at 9.8x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -123.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.
Bull Case : NMTC
The strongest argument for NMTC centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 72.5% demonstrates continued momentum.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : NMTC
The primary concerns for NMTC are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
DXCM profiles as a mature stock while NMTC is a hypergrowth play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.45 — expect wider price swings.
NMTC is growing revenue faster at 72.5% — sustainability is the question.
DXCM generates stronger free cash flow (449M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (72/100 vs 32/100), backed by strong 19.3% margins and 15.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Neuroone Medical Technologies Corp
HEALTHCARE · MEDICAL DEVICES · USA
NeuroOne Medical Technologies Corporation is a medical technology company. The company is headquartered in Eden Prairie, Minnesota.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?